RecruitingNot ApplicableNCT07302230

Home-Based Physical Activity Program With Digital App Versus Health Education Group for Improving Physical Activity Among Patients With Non-muscle Invasive Bladder Cancer, The EMPOWER Trial

The EMPOWER Trial: Evaluating a Home-Based Physical Activity Program (PAP) With the ExerciseRx™ Digital Platform vs. Health Education Group (HEG) in People With Non-Muscle Invasive Bladder Cancer


Sponsor

University of Washington

Enrollment

100 participants

Start Date

Mar 11, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

This clinical trial compares how well a home-based personalized physical activity program (PAP) that is delivered by a digital application (app) (the ExerciseRx app) works compared to health education in improving physical activity for patients with bladder cancer that has not reached the muscle wall of the bladder (non-muscle invasive). For people who are not physically active, previous studies have shown that increasing step counts can reduce incidence of death, reduce frailty, and reduce healthcare costs. The ExerciseRx app tracks adherence to home exercise, adapts step count goals based on the patient's progress, and provides encouraging feedback and motivation from the healthcare team. Additional features include activity summaries, progress towards current goal, nudges, helpful facts about the benefits of activity, and ideas for how to incorporate daily movement. A home-based PAP using the ExerciseRx app may work better in increasing physical activity among patients with non-muscle invasive bladder cancer compared to a health education only group.


Eligibility

Min Age: 18 Years

Inclusion Criteria7

  • Adults (age \>= 18 years)
  • Prior diagnosis of non-muscle invasive bladder cancer (NMIBC), currently on surveillance or receiving maintenance intravesical therapy (including intravesical chemotherapy, immunotherapy)
  • Classified as insufficiently active on the Physical Activity as a Vital Sign (PAVS) assessment
  • Has an Android or Apple Smartphone/Tablet
  • Ambulatory
  • English-speaking
  • Willing and able to participate in study activities and sign the informed consent form

Exclusion Criteria10

  • Severe cognitive or memory impairment/dementia precluding ability to follow instructions or participate in survey assessments
  • Inability to read or understand English
  • Lack of access or lack of sufficient facility to use an Android or iOS smart device with the minimum criteria to run the ExerciseRx app
  • Not receiving treatment at University of Washington (UW)
  • Orthopedic, neurologic, or other problems that prevent safe ambulation and protocol adherence. Information on prior falls and other recent orthopedic or neurologic problems will be used to make judgment about protocol eligibility
  • Inability/Unwillingness to participate in a personalized exercise program
  • Current diagnosis with muscle-invasive or metastatic bladder cancer
  • Uncontrolled or concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Lack of access or lack of sufficient facility to use an Android or iOS smart device with the minimum criteria for using the ExerciseRx app
  • Participation in a clinical trial that does not permit enrollment in the EMPOWER trial

Interventions

OTHERInternet-Based Intervention

Given access to the ExerciseRx app

OTHERBest Practice

Given instruction to continue physical activity as usual

OTHERInternet-Based Intervention

Given access to the ExerciseRx app locked to the baseline home screen

OTHERExercise Intervention

Complete home exercise sessions

OTHERHealth Telemonitoring

Given a FitBit® to wear continuously

OTHEREducational Intervention

Given NCCN Survivorship for Healthy Living Guidelines pamphlet

OTHERQuestionnaire Administration

Ancillary studies

OTHERInterview

Ancillary studies

OTHERElectronic Health Record Review

Ancillary studies


Locations(1)

Fred Hutch/University of Washington Cancer Consortium

Seattle, Washington, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07302230


Related Trials